Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
In this multicentric, double-blind, randomized,placebo-controlled study, the investigators
hypothesized that rifaximin might act on Gram-negative bacteria and intestinal bacterial
overgrowth(IBO) thereby inhibiting lipopolysaccharides(LPS)-mediated proinflammatory cytokine
production. This work evaluates the efficacy of 6 months administration of rifaximin in NAFLD
patients.